REGN
Regeneron Pharmaceuticals, Inc.
Cash flow statement
| USDLine, in USD | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 4.85B | 4.98B | 4.42B | 4.59B | 5.01B | 7.08B | 2.62B | 2.43B | 2.20B | 1.31B | 1.49B | 1.33B | 0.75B | 0.59B | −75M | −0.14B | 99M | −70M | −89M |
| 1.02B | 0.90B | 0.76B | 0.72B | 0.59B | 0.55B | 0.61B | 0.43B | 0.38B | 0.27B | 0.51B | 0.68B | 0.33B | 0.16B | 49M | 57M | 100M | 97M | 35M | |
| Free cash flow | 3.83B | 4.08B | 3.66B | 3.88B | 4.42B | 6.53B | 2.00B | 2.00B | 1.81B | 1.03B | 0.97B | 0.65B | 0.42B | 0.43B | −0.12B | −0.20B | −467K | −0.17B | −0.12B |
| Depreciation and amortization | 513M | 544M | 483M | 421M | 341M | 286M | 236M | 210M | 148M | 146M | 105M | 75M | 53M | 41M | 37M | 31M | 20M | 14M | 11M |
| Stock-based compensation | 1.01B | 0.99B | 0.98B | 0.89B | 0.73B | 0.60B | 0.43B | 0.46B | 0.43B | 0.51B | 0.56B | 0.46B | 0.32B | 0.22B | 94M | 56M | 40M | 31M | 33M |
| Buybacks | 3.04B | 3.44B | 2.60B | 2.24B | 2.08B | 1.65B | 5.85B | 0.28B | 4.4M | 0 | 0 | — | — | — | — | — | — | — | — |
| Dividends paid | 383M | 370M | 0 | 0 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividends per share | 3.70 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Free cash flow margin | 22.6% | 28.4% | 25.8% | 29.5% | 36.3% | 40.6% | 23.6% | 30.5% | 35.2% | 17.6% | 20.0% | 15.9% | 14.9% | 20.5% | −9.0% | −44.6% | −0.1% | −44.1% | −52.0% |